Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
- PMID: 35765655
- PMCID: PMC9189996
- DOI: 10.1016/j.csbj.2022.05.057
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
Abstract
Repositioning or repurposing drugs account for a substantial part of entering approval pipeline drugs, which indicates that drug repositioning has huge market potential and value. Computational technologies such as machine learning methods have accelerated the process of drug repositioning in the last few decades years. The repositioning potential of type 2 diabetes mellitus (T2DM) drugs for various diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases have been widely studied. Hence, the related summary about repurposing antidiabetic drugs is of great significance. In this review, we focus on the machine learning methods for the development of new T2DM drugs and give an overview of the repurposing potential of the existing antidiabetic agents.
Keywords: AD, Alzheimer’s Disease; AEs, autoencoders; ASCVD, atherosclerotic cardiovascular disease; Antidiabetic drugs; CNNs, convolutional neural networks; CV, cardiovascular; CVD, cardiovascular diseases; DBNs, deep brief networks; DDA, drug-disease association; DDI, drug-drug interaction; DL, deep learning; DM, diabetes mellitus; DNNs, deep neural networks; DPP-4, dipeptidyl peptidase 4; DTI, drug-target interaction; Deep learning; Drug repositioning; Drug repurposing; GLP-1, glucagon-like peptide 1; GNNs, graph neural networks; ML, machine learning; Machine learning; PD, Parkinson’s Disease; PI3K/AKT, phosphatidylinositol 3-kinase/AKT; RNNs, recurrent neural networks; SGLT-2, sodium-glucose cotransporter 2; T2DM; T2DM, type 2 diabetes mellitus; TZD, thiazolidinedione; cAMP/PKA, cyclic adenosine monophosphate/protein kinase A.
© 2022 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures


Similar articles
-
Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.Curr Med Res Opin. 2020 Mar;36(3):403-409. doi: 10.1080/03007995.2019.1706043. Epub 2020 Jan 6. Curr Med Res Opin. 2020. PMID: 31855074
-
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.Neural Regen Res. 2019 May;14(5):745-748. doi: 10.4103/1673-5374.249217. Neural Regen Res. 2019. PMID: 30688255 Free PMC article. Review.
-
Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.Int Rev Neurobiol. 2020;155:37-64. doi: 10.1016/bs.irn.2020.02.010. Epub 2020 Aug 11. Int Rev Neurobiol. 2020. PMID: 32854858 Review.
-
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.Curr Med Res Opin. 2007 Apr;23(4):919-31. doi: 10.1185/030079906x162746. Curr Med Res Opin. 2007. PMID: 17407649 Review.
-
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.Clin Ther. 2016 Jun;38(6):1288-1298. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19. Clin Ther. 2016. PMID: 27210264
Cited by
-
Emodin, a rising star in the treatment of glycolipid metabolism disorders: a preclinical systematic review and meta-analysis.PeerJ. 2025 May 15;13:e19221. doi: 10.7717/peerj.19221. eCollection 2025. PeerJ. 2025. PMID: 40386230 Free PMC article.
-
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.Mol Biomed. 2024 Sep 28;5(1):40. doi: 10.1186/s43556-024-00204-z. Mol Biomed. 2024. PMID: 39333445 Free PMC article. Review.
-
Effects of antidiabetic agents on platelet characteristics with implications in Alzheimer's disease: Mendelian randomization and colocalization study.Heliyon. 2024 May 9;10(10):e30909. doi: 10.1016/j.heliyon.2024.e30909. eCollection 2024 May 30. Heliyon. 2024. PMID: 38778961 Free PMC article.
-
Empagliflozin: Primus Inter Pares Among Sodium-Glucose Cotransporter-2 Inhibitors?J Cardiovasc Pharmacol. 2024 Sep 1;84(3):271-275. doi: 10.1097/FJC.0000000000001605. J Cardiovasc Pharmacol. 2024. PMID: 39027982 Free PMC article. Review.
-
Vir2Drug: a drug repurposing framework based on protein similarities between pathogens.Brief Bioinform. 2023 Jan 19;24(1):bbac536. doi: 10.1093/bib/bbac536. Brief Bioinform. 2023. PMID: 36513376 Free PMC article.
References
-
- Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683. - PubMed
-
- Langedijk J., et al. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027–1034. - PubMed
-
- Bertolini F., Sukhatme V.P., Bouche G. Drug repurposing in oncology–patient and health systems opportunities. Nat Rev Clin Oncol. 2015;12(12):732–742. - PubMed
Publication types
LinkOut - more resources
Full Text Sources